Companies/RO/AROBS

AROBS TRANSILVANIA SOFTWARE S.A.

Last · —$0.73-0.004 (-0.54%)live · yahoo · 2s ago
Vol 507.5K ≈ 370.4K
Market cap——
P/E · TTM12.2fwd — · eps —
Beta—vs S&P 500
Div yield—annual · TTM
52w range
——
Volume—session

Issuer

Legal nameAROBS TRANSILVANIA SOFTWARE S.A.
HQRomania (RO)
ListingRO AROBS
ISINROWMR49B0RG5
SectorTechnology
IndustryIT Services & Consulting
CurrencyUSD
Entity registryisin:ROWMR49B0RG5
Org IDAROBS
Websitearobs.com
Employees1,064
AddressARoBS Transilvania Software SA Strada Donath, Nr. 11 400301, Cluj Napoca +40 75 490 8742
Loading chart…

OpenFilings analyst

Our analyst

Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.

Promising strategy, but insufficiently quantified outlook and elevated execution risk.

Latest call · H1 2026

Hold: the call supports a credible U.S./AI-led growth strategy, but it did not provide enough quantified evidence to justify buying after the call.

Management cited a strong H2 2026/2027 pipeline, cash equivalent to roughly 40% of annual turnover and RON 6 million of contracted revenue expected by year-end, yet it disclosed no detailed contribution, timing or profitability for the large public-sector contracts and remains exposed to AI-driven pricing pressure and execution risk.

Themes
  • Public Sector Contracts
  • Ai Pricing
  • Us Growth
  • M&A Strategy
  • Buyback
  • Bet Index
+1

Near term

Buyback pace should remain around 100,000 shares per day because of the 25% of average daily volume regulatory limit; the 30 million-share target will therefore be executed gradually.

Public-sector contract execution is the key near-term catalyst, but several recently awarded projects have not started and implementation calendars remain unclear.

Management may update its budget if the strong H2 pipeline converts positively; current commentary is not firm guidance.

Only RON 6 million from the National House of Public Pensions contract is specifically identified as remaining contracted revenue, expected to be recognized by year-end.

Longer term

U.S. expansion is broad-based across technology/software, financial services and life sciences, with medical embedded systems and FDA-related drug testing identified as additional opportunities.

AI could expand the addressable market and support margins on fixed-scope, outcome-based work, but the shift away from hourly pricing may change revenue quality and make growth harder to assess.

AROBS intends to pursue organic growth and focused M&A simultaneously, targeting new verticals, customer segments and geographies; its low indebtedness and substantial cash provide acquisition capacity.

The competitive moat remains unproven: AI capabilities are becoming a basic requirement, while differentiation depends on industry expertise, delivery quality and productivity against lower-cost markets such as India, Ukraine and Serbia.

Potential BET inclusion could improve liquidity and visibility, but management emphasized that inclusion depends on sustained results, liquidity and free float rather than a specific near-term action.

Red flags

Management declined to quantify AROBS's share, implementation timing or economics for the CNA, ADR and ARBDD contracts, despite the headline contract values.

Management said each cited project is below 10% of group turnover, limiting the likely near-term impact of the large reported contract values and raising the risk that investors overestimate backlog conversion.

The company acknowledged that many customers initially approached AI primarily as a cost-reduction tool, creating current headwinds and potential pricing pressure.

M&A targets, valuation multiples, synergies and funding structure remain undisclosed while management continues to evaluate multiple acquisitions.

The response to AI cannibalization was largely strategic rather than evidentiary: no customer-level data, realized pricing trends or quantified productivity benefits were provided.

Recommendation history

OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.

Upcoming earnings

1 event
4:00 PM UTC+1
Period
Sep 2026
Est. EPS
—
Est. revenue
0

Earnings transcripts

10 recent

Documents